Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Sues Invitrogen for Patent Infringement

SAN FRANCISCO, Nov. 28 – Contending patent violations, Incyte Genomics filed suit against Invitrogen on Nov. 21 in the US District Court of the Southern District of California.

The lawsuit follows Invitrogen’s own patent violations suit against Incyte , filed Oct. 17 in the US District Court of Delaware. 

Incyte’s lawsuit contends multiple patent violations, including infringements against gene patents in connection with Invitrogen’s GeneStorm Clones product, RNA amplification and gene expression analysis, and microarray fabrication, according to the complaint filed with the court.

Incyte, which said in court papers that “Invitrogen’s infringements of the… patents has been willful and deliberate” said Incyte “has been and continues to be damaged in its collective business and property, including the loss of substantial profits in an amount to be determined at trial.”

“As [the claims of patent infringement] relates to our GeneStorm clones, it appears to apply to only a dozen of the thousands of clones we sell,” Paul Goodson, vice president of investor relations at Carlsbad, Calif.-based Invitrogen, told GenomeWeb . “As it relates to other technologies, we think either we didn’t infringe, they are not valid, or they are unenforceable.” 

“We sued them not too long ago,” added Goodson. “We think this suit they have filed is a defensive tactic.”

Incyte declined to comment.

Incyte, based in Palo Alto, Calif., is currently undergoing a company-wide restructuring, including the announcement in October of approximately 400 layoffs and the appointment earlier this week of a new CEO and president

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.